{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '15', 'CLINICAL TRIAL PROTOCOL AMENDMENTS', 'All appendices attached hereto and referred to herein are made part of this clinical trial protocol.', 'The Investigator should not implement any deviation from, or changes to the clinical trial protocol', 'without agreement by the Sponsor and prior review and documented approval/favorable opinion', 'from the IRB/IEC and/or notification/approval of health authorities (competent regulatory', 'authority) of an amendment, as required by local regulation, except where necessary to eliminate', 'an immediate hazard(s) to clinical trial patients, or when the change(s) involves only logistical or', 'administrative aspects of the trial. Any change agreed upon will be recorded in writing, the', 'written amendment will be signed by the Investigator and by the Sponsor and the signed', 'amendment will be filed with this clinical trial protocol.', 'Any amendment to the clinical trial protocol requires written approval/favorable opinion by the', 'IRB/IEC prior to its implementation, unless there are overriding safety reasons.', 'In case of substantial amendment to the clinical trial protocol, approval from the health authorities', '(competent regulatory authority) will be sought before implementation.', 'In some instances, an amendment may require a change to the ICF. The Investigator must receive', 'an IRB/IEC approval/favorable opinion concerning the revised ICF prior to implementation of the', 'change and patient signature should be recollected if necessary.', 'Property of the Sanofi Group - strictly confidential', 'Page 98', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '16', 'BIBLIOGRAPHIC REFERENCES', '1. National Multiple Sclerosis Society, 2013 Annual Report.', '2. Yeh EA, Chitnis T, Krupp L, Ness J, Chabas D, Kuntz N, et al. US Network of Pediatric', 'Multiple Sclerosis Centers of Excellence. Pediatric Multiple Sclerosi. Nat Rev Neurol.', '2009;5(11):621-31.', '3. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in', 'an MS center population from the Northeastern United States. Mult Scler. 2009;15(5):627-31.', '4. Yeh EA. Current therapeutic options in pediatric multiple sclerosis. Curr Treat Options', 'Neurol. 2011;13(6):544-59.', '5. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of', 'multiple sclerosis with childhood onset. Adult Neurology Departments KIDMUS Study', 'Group. N Engl J Med. 2007;356(25):2603-13.', '6. Gusev E, Boiko A, Bikova O, Maslova O, Guseva M, Boiko S, et al. The natural history of', 'early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol', 'Neurosurg. 2002;104(3):203-7.', '7. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British', 'Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study.', 'Neurology. 2002;59(7):1006-10.', '8. Narula S. New Perspectives in Pediatric Neurology-Multiple Sclerosis.', 'CurrProblPediatrAdolescHealthCare. 2016;46:62-9.', '9. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar A, Ghezzi A, et al. International Pediatric', 'MS Study Group Clinical trials Summit: Meeting report. Neurology 2013;80;1161-8.', '10. Krupp LB, Banwell B, Tenembaum S, International Pediatric MS Study Group. Consensus', 'definitions proposed for pediatric multiple sclerosis and related disorders. Neurology.', '2007;68( Supp 2):S7-12.', '11. Ghezzi A, Pozzilli C, Liguori M, Marrosu MG, Milani N, Milanese C, et al. Prospective study', 'of multiple sclerosis with early onset. Mult Scler. 2002;8:115-8.', '12. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International', 'Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-', 'mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.', 'Mult Scler. 2013;19(10):1261-7.', '13. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-', 'analysis of randomised trials. Lancet Neurol. 2013;12(7):669-76.', 'Property of the Sanofi Group - strictly confidential', 'Page 99', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}